Clinical trial

Evaluation of Neuregulin-4 (NRG4) Levels in Obese and Non-Obese Patients With Type 2 Diabetes Mellitus

Opening soon · Not applicable · 1 countries · Registry ID NCT07734558

Opening soonNot applicableObservational

What this study is about

This prospective observational study aims to evaluate serum Neuregulin-4 (NRG4) concentrations in obese and non-obese adults with Type 2 Diabetes Mellitus (T2DM) and to investigate their association with obesity status, insulin resistance, and different antidiabetic treatment regimens. Participants will be categorized into five predefined groups according to obesity status and treatment regimen, including SGLT2 inhibitor users, non-SGLT2 oral antidiabetic therapy users, SGLT2 combination therapy users, newly diagnosed treatment-naïve patients, and healthy controls. Clinical, anthropometric, and laboratory parameters including fasting plasma glucose, HbA1c, estimated glomerular filtration rate (eGFR), body mass index, waist circumference, waist-to-hip ratio, and serum NRG4 concentrations will be evaluated. The study aims to determine whether NRG4 may serve as a novel biomarker reflecting metabolic status and treatment response in patients with T2DM.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 65 Years

SexAll

Healthy volunteersAccepted

ConditionType 2 Diabetes Mellitus (T2DM), Obesity Type 2 Diabetes Mellitus, Insulin Resistance

Full registry criteria

Inclusion Criteria: * Age 18-65 years * Newly diagnosed treatment-naïve T2DM * T2DM treated for at least 6 months * BMI \>30 kg/m² * BMI \<25 kg/m² * No pregnancy * No breastfeeding * No active infection * No inflammatory disease * Written informed consent Exclusion Criteria: * Age \<18 years * Pregnancy * Breastfeeding * Active infection * Rheumatologic disease * Refusal to participate

Treatments and study arms

The registry does not list a named intervention.

Primary outcomes

Serum Neuregulin-4 (NRG4) Levels in Obese and Non-Obese Type 2 Diabetic PatientsBaseline (Day 0)

The primary outcome of this study is the evaluation and comparison of serum Neuregulin-4 (NRG4) levels among obese and non-obese patients with Type 2 Diabetes Mellitus receiving different antidiabetic treatment modalities, as well as healthy control subjects.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Kanuni Sultan Süleyman Training and Research Hospital🌐 Istanbul, Turkey (Türkiye)

Open map

gülden ANATACAContact

Email · Call +905059284244